NEU 3.50% $14.05 neuren pharmaceuticals limited

Share Price, page-7273

  1. 2,168 Posts.
    lightbulb Created with Sketch. 572
    Hi CC,

    Not sure how they got their EPS.

    P/E ratio of 25 has been used on this forum as a conservative bench mark for some time, with some good reasoning justifying for higher P/E due to NEU’s future growth prospects which I think would logically convert should phase 2 trails have success per gaps then P/E of 40 - 50 could then be applied.

    Based on Neu’ half yearly profit of $48m should give usEPS .38, hard to get a clear shot at future revenues as Acadia not giving us much, but revenue I think we’ll over $200m for this FY given ROW deal and if Daybue continues as we all believe uptake is they no reason revenues could be forward looking of $100-$150m p.a given milestone, PRV or a upfront for 2591.

    EPS of $1 or more is potentially not far away x 25 a share price of $25-$30 of where we should be heading quickly realistically!

    hopefully this period is just funds/punters loading their boots for this next transition in Neu share price as important milestones get hit, Nov sales forcast from Acadia, Dec PM ph 2 results, new year longer term forward sales forcast annual and balance x3 2591 results and NEU’s future to be known in next 3-6 months
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$14.05
Change
-0.510(3.50%)
Mkt cap ! $1.795B
Open High Low Value Volume
$14.38 $14.42 $13.94 $6.419M 454.6K

Buyers (Bids)

No. Vol. Price($)
1 500 $13.99
 

Sellers (Offers)

Price($) Vol. No.
$14.07 6644 4
View Market Depth
Last trade - 16.10pm 04/10/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.